Company intelligence / Profile preview

Highrock

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

HighRock Therapeutics is a pre-clinical stage biotechnology company dedicated to the discovery and development of transformative oncology treatments. Founded by Dr. H. Michael Shepard, the scientist credited with the discovery of Herceptin, the company focuses on identifying and targeting novel pathways within the tumor microenvironment. HighRock aims to overcome resistance mechanisms in current cancer therapies through the application of precision medicine and advanced antibody engineering. Their lead programs are currently in the discovery and early development phases, targeting various solid tumor indications.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Beyond the preview

Go deeper on Highrock.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Highrock.

Explore the full profile